|
 Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY) GlaxoSmithKline plc (NYSE: GSK) won a joint $2.1 billion U.S. federal funding award.Here're the key catalysts for the unfolding week:Conferences72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8PDUFA DatesFDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through.Trevena Inc (NASDAQ: TRVN) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.FDA is also due to rule on Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) exertional heat stroke drug ryanodex Saturday. The original PDUFA date was pushed back a month as the FDA finds it hard to keep up with scheduling commitments due to COVID-19.Clinical ReadoutsBioSig Technologies Inc's (NASDAQ: BSGM) CEO Kenneth Londoner, will present at the Proactive Investors One2One Virtual Event Tuesday an update on Phase 2 clinical study of merimepodib in combination with remdesiv
|
|
Private Label